6/29/23, 1:41 AM POPLAR Pathway Feedback Search Clinical Topics Home Studies POPLAR POPLAR Disease Non-small cell lung cancer Trial question What is the role of atezolizumab in patients with previously treated non-small cell lung cancer? Study design Multi-center Open label RCT Population Characteristics of study participants 41.0% female N = 287 59.0% male 287 patients (118 female, 169 male) Inclusion criteria: patients with previously treated non-small cell lung cancer Key exclusion criteria: active or untreated CNS metastases, history of pneumonitis, autoimmune or chronic viral diseases, or previous treatment with docetaxel, CD137 agonists, anti-CTLA4, anti- PD-L1, or anti-PD-1 therapeutic antibodies, or PD-L1-PD-1 pathway-targeting agents Interventions N=144 atezolizumab (intravenous dosage of 1200 mg once every 3 weeks) N=143 atezolizumab (intravenous dosage of 75 mg/m once every 3 weeks) Primary outcome Overall survival https://web.pathway.md/studies/recbfmlgbL3W41z3j 1/2 6/29/23, 1:42 AM POPLAR Pathway 12.6 months 12.6 9.7 9.4 months 6.3 months 3.1 months Significant increase 0.0 months Atezolizumab Atezolizumab Significant increase in overall survival (12.6 months vs. 9.7 months; HR 1.37, 95% CI 1.01 to 1.89) Secondary outcomes No significant difference in progression-free survival (2.7 months vs. 3 months; HR 0.94, 95% CI 0.72 to 1.23) Safety outcomes Significant differences in treatment-related grade 3-4 adverse events (11% vs. 39%), discontinuation because of adverse events (8% vs. 22%), and death from treatment-related adverse event (< 1% vs. 2%). Conclusion In patients with previously treated non-small cell lung cancer, atezolizumab was superior to atezolizumab with respect to overall survival. Reference Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. Open reference URL https://web.pathway.md/studies/recbfmlgbL3W41z3j 2/2